5-Azacytidine for the treatment of myelodysplastic syndromes

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 9, 2013, Pages 1255-1268

  Krawczyk, Janusz ^a   Keane, Niamh ^b   Freeman, Ciara Louise ^c   Swords, Ronan ^d   O'Dwyer, Michael ^e   Giles, Francis J ^e  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d UNIVERSITY OF MIAMI   (United States)

^e NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

5 azacytidine; Epigenetic therapy; Histone deacetylase inhibitors; Hypomethylation; Myelodysplastic syndrome

Indexed keywords

AZACITIDINE;

ANEMIA; ARTICLE; CONSTIPATION; DEFENSE MECHANISM; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; FEVER; HIGH RISK PATIENT; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MAINTENANCE THERAPY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; DRUG APPROVAL; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; QUALITY OF LIFE; SURVIVAL;

EID: 84877887782     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.794222     Document Type: Article

References (76)

1. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992;82(2):358-67
2. Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011;117(26):7121-5
3. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000;9(16):2395-402
4. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349(21):2042-54
5. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999;99(5):451-4
6. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 2009;15(12):3927-37
7. Mufti G, List AF, Gore SD, et al. Myelodysplastic syndrome. Hematol Am Soc Hematol Educ Program 2003;176-99
8. Cazzola M, Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am 2010;24(2):459-68
9. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364(26):2496-506
10. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28(4):605-13
11. Oliva EN, Finelli C, Santini V, et al. Quality of life and physicians' perception in myelodysplastic syndromes. Am J Blood Res 2012;2(2):136-47
12. Vogler WR, Miller DS, Keller JW. 5-azacytidine (nsc 102816): A new drug for the treatment of myeloblastic leukemia. Blood 1976;48(3):331-7
13. Glover AB, Leyland-Jones BR, Chun HG, et al. Azacitidine: 10 years later. Cancer Treat Rep 1987;71(7-8):737-46
14. Lee T, Karon M, Momparler RL. Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. Cancer Res 1974;34(10):2482-8
15. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123(1):8-13
16. Li LH, Olin EJ, Buskirk HH, et al. Cytotoxicity and mode of action of 5-azacytidine on l1210 leukemia. Cancer Res 1970;30(11):2760-9
17. Fabre C, Grosjean J, Tailler M, et al. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: nfkappab inhibition in malignant myeloblasts. Cell Cycle 2008;7(14):2139-45
18. Costantini B, Kordasti SY, Kulasekararaj AG, et al. 5-azacytidine specifically depletes regulatory t cells (tregs) in myelodysplastic syndrome (mds) patients. ASH Annual Meeting Abstracts 2011;118(21):787
19. Marcucci G, Silverman L, Eller M, et al. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005;45(5):597-602
20. Chabot GG, Bouchard J, Momparler RL. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol 1983;32(7):1327-8
21. Israili ZH, Vogler WR, Mingioli ES, et al. The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. Cancer Res 1976;36(4):1453-61
22. Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117(2):403-11
23. Breccia M, Loglisci G, Cannella L, et al. Application of french prognostic score to patients with international prognostic scoring system intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response. Leuk Lymphoma 2012;53(5):985-6
24. van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (mds), chronic myelomonocytic leukaemia (cmml) and acute myeloid leukaemia (aml) patients in the dutch azacitidine compassionate named patient programme. Br J Haematol 2011;155(5):599-606
25. Sanna A, Cannella L, Gozzini A, et al. Comorbidities indexes in patients treated with 5-azacitidine are a an useful and easily applicable tool to refine prognostic evaluation. ASH Annual Meeting Abstracts 2010;116(21):606
26. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114(13):2764-73
27. Blum W, Garzon R, Klisovic RB, et al. Clinical response and mir-29b predictive significance in older aml patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107(16):7473-8
28. Follo MY, Russo D, Finelli C, et al. Epigenetic regulation of nuclear pi-plcbeta1 signaling pathway in low-risk mds patients during azacitidine treatment. Leukemia 2012(26(5):943-50
29. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of tet2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25(7):1147-52
30. Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase i/ii study. Leuk Lymphoma 2012;53(1):110-17
31. McCredie KB, Bodey GP, Burgess MA, et al. Treatment of acute leukemia with 5-azacytidine (nsc-102816). Cancer Chemother Rep 1973;57(3):319-23
32. Saiki JH, Bodey GP, Hewlett JS, et al. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a southwest oncology group study. Cancer 1981;47(7):1739-42
33. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009;114(13):2764-73
34. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group b. J Clin Oncol 2002;20(10):2429-40
35. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10(3):223-32
36. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011;117(12):2697-702
37. Gerds AT, Gooley TA, Estey EH, et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with mds. Biol Blood Marrow Transplant 2012;18(8):1211-18
38. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group b. J Clin Oncol 2006;24(24):3895-903
39. Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an italian named patient program. Cancer 2010;116(6):1485-94
40. Navada SC, Silverman LR. Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions. Curr Hematol Malig Rep 2011;6(1):5-12
41. Santini V. Azacitidine in lower-risk myelodysplastic syndromes. Leukemia Res 2009;33(Suppl 2):22-6
42. Grovdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (mds) or acute myeloid leukaemia following mds in complete remission after induction chemotherapy. Br J Haematol 2010;150(3):293-302
43. Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the societe francaise de greffe de moelle et de therapie-cellulaire and the groupe-francophone des myelodysplasies. J Clin Oncol 2012;30(36):4533-40
44. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010;6(23):5420-31
45. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in mds or aml patients after allogeneic hsct: results of the relaza trial. Leukemia 2012(3):381-9
46. Schroeder T, Czibere A, Kroger N, et al. Phase ii study of azacitidine (vidaza(r), aza) and donor lymphocyte infusions (dli) as first salvage therapy in patients with acute myeloid leukemia (aml) or myelodysplastic syndromes (mds) relapsing after allogeneic hematopoietic stem cell transplantation (allo-sct): Final results from the azarela-trial (nct-00795548). ASH Annual Meeting Abstracts 2011;118(21):656
47. Ornstein MC, Sekeres MA. Combination strategies in myelodysplastic syndromes. Int J Hematol 2012;5(1):26-33
48. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21(1):103-7
49. Voso MT, Santini V, Finelli C, et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009;15(15):5002-7
50. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66(12):6361-9
51. Prebet T, Gore SD, Sun Z, et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the us leukemia intergroup trial e1905. ASH Annual Meeting Abstracts 2010;6(21):601
52. Garcia-Manero G, Estey EH, Jabbour E, et al. Final report of a phase ii study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (mds) or acute myelogenous leukemia (aml) not eligible for clinical trials because poor performance and presence of other comorbidities. ASH Annual Meeting Abstracts 2011;118(21):608
53. Raza A, Mehdi M, Mumtaz M, et al. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008;113(7):1596-604
54. Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012;120(25):4945-51
55. Moon JH, Lee SJ, Lee YJ, et al. Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast. Ann Hematol 2012(3):367-73
56. Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010;6(17):3163-70
57. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009(11):1850-6
58. Sekeres MA, Maciejewski JP, Donley DW, et al. A study comparing dosing regimens and efficacy of subcutaneous to intravenous azacitidine (aza) for the treatment of myelodysplastic syndromes (mds). ASH Annual Meeting Abstracts 2009;14(22):3797
59. Garcia-Manero G, Gore SD, Cogle C, et al. Phase i study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011;29(18):2521-7
60. Laille E, Shi T, Garcia-Manero G, et al. Extended dosing of oral azacitidine (cc-486) for 14 and 21 days provides more effective methylation reversal than a 7-day schedule. ASH Annual Meeting Abstracts 2012;0(21):1337
61. Prebet T, Thepot S, Gore SD, et al. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. Haematologica 2013;98(2):e18-19
62. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;29(24):3322-7
63. Seetharam M, Fan AC, Tran M, et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with on 01910. Na. Leuk Res 2012;36(1):98-103
64. Kantarjian H, Garcia-Manero G, O'Brien S, et al. Phase i clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 2010;28(2):285-91
65. Garcia-Manero G, Luger S, Venugopal P, et al. A randomized phase 2 study of sapacitabine, an oral nucleoside analogue, in older patients with mds refractory to hypomethylating agents. ASH Annual Meeting Abstracts 2010;116(21):1857
66. Faderl S, Garcia-Manero G, Jabbour E, et al. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 2012;118(3):722-8
67. Faderl S, Garcia-Manero G, Estrov Z, et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010;28(16):2755-60
68. Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol 2010;85(2):130-8
69. Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome- A systematic review and meta-analysis. Haematologica 2010;95(2):303-10
70. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with who-defined acute myeloid leukaemia compared with conventional care regimens: An update. Ecancermedicalscience 2008;2:121
71. Sekeres MA, List AF, Cuthbertson D, et al. Phase i combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010;28(13):2253-8
72. Garcia-Manero G, Yang AS, Klimek V, et al. Phase i/ii study of mgcd0103, an oral isotype-selective histone deacetylase (hdac) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (mds) and acute myelogenous leukemia (aml). ASH Annual Meeting Abstracts 2007;110(11):444
73. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110(7):2302-8
74. Raffoux E, Cras A, Recher C, et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010;1(1):34-42
75. Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-m3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma 2008;49(11):2141-7
76. Scott BL, Ramakrishnan A, Storer B, et al. Prolonged responses in patients with mds and cmml treated with azacitidine and etanercept. Br J Haematol 2010;148(6):944-7